TABLE 2.

List of CIDP studies with an improvement primary endpoint or studies with a stability vs deterioration primary endpoint ⁴ , ⁸ , ⁹ , ¹⁰ , ¹¹ , ¹² , ¹³ , ¹⁴ , ¹⁷ , ¹⁸ , ²⁰ , ²¹ , ²³

Study	Active treatment	Primary endpoint measure	Sample size			Dose	Duration of study/phase	Placebo arm response	Active arm response
			Total	Placebo	Active
CIDP studies with an improvement endpoint
Hughes et al 14 (ICE phase 1)	Gamunex (IVIG)	Total adjusted INCAT	117	58	59	1 g/kg every 3 weeks	24 weeks	21% improved	54% improved
Mendell et al 17	Gammar IV (IVIG)	AMS	53	23	30	1 g/kg every 3 weeks	6 weeks	9% improved	38% improved
Hadden et al 10	Interferon beta 1a	Improvement in any 3 of 8 clinical measures a	10	Crossover study		3 MIU 3x per week 2 weeks and 6 MIU for 10 weeks	12 weeks	20% improved	10% improved
Hahn et al 12	IVIG	NDS, CG, and grip strength	30	Crossover study		0.4 g/kg bw over 5 days	9 weeks	17% improved	63% improved
Hahn et al 11	Plasma exchange	NDS, CG, andgrip strength	18	Crossover study		10 exchanges over 4 weeks	9 weeks	0% improved	80% improved
Vermeulen et al 21	IVIG	Rankin scale and MRC sum score	28	13	15	0.4 g/kg bw over 5 days	3 weeks	23% improved	27% improved
van Doorn et al 20	IVIG	Rankin scale	7	Crossover study		0.4 g/kg bw over 5 days	Unclear	0% improved	100% improved
Dyck et al 8	Plasma exchange	NDS	29	14	15	Twice a week	3 weeks	0% improved	33% improved
Dyck et al 9	Plasma exchange	NDS	14	7	7	Twice a week	3 weeks	43% improved	57% improved
CIDP studies with a stability vs deterioration endpoint
Hughes et al 13 (FORCIDP)	Fingolimod	Total adjusted INCAT	106	52	54	0.5 mg daily	3 years	43% non‐deterioration	42% non‐deterioration
van Schaik et al 4 (PATH)	Hizentra (SCIG)	Total adjusted INCAT	172	51 b	115 c	0.2 or 0.4 g/kg weekly	24 weeks	37% non‐deterioration	61%‐67% non‐deterioration
Markvardsen et al 16	Subcuvia (SCIG)	IKS	30	15	14	1:1 previous IVIG dose	12 weeks	33% non‐deterioration	79% non‐deterioration
RMC et al 18 (RMC group)	Methotrexate	Reduction in mean weekly dose d	59	32	27	7.5‐15 mg weekly	32 weeks	44% maintained	52% maintained
Hughes et al 14 (ICE phase 2)	Gamunex (IVIG)	Total adjusted INCAT	57	26	31	1 g/kg every 3 weeks	24 weeks	58% non‐deterioration	87% non‐deterioration

Abbreviations: AMS, average muscle score; CG, functional clinical grade; IKS, isokinetic strength; INCAT, inflammatory neuropathy cause and treatment; IVIG, intravenous immunoglobulin; MRC, Medical Research Council; NDS, neurological disability scale; SCIG, subcutaneous immunoglobulin.

^aClinical measures included: timed 10‐m walk, ambulation index, expanded Medical Research Council (MRC) sum score, nine‐hole peg test time, functional independence measure, Hammersmith motor ability, a new Guy's neurological disability scale, and the EuroQoL quality of life scale.

^b20% reduction in mean weekly dose of IVIG or corticosteroids in last 4 weeks compared with first 4 weeks.

^cOf the 172 subjects randomized in the original paper, six from the placebo group were removed from our analysis due to either withdrawing without relapse (n = 4) or erroneously entering the restabilization phase (n = 2). This results in n = 51 for the placebo arm.

^dCombined SCIG‐treatment groups (0.2 g/kg, n = 57 and 0.4 g/kg, n = 58).